Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
CSC letter to CMS commenting on the Medicare Prescription Payment Plan (M3P) Guidance Part Two. Comments focus on outreach, education, and communication requirements for Part D Sponsors; and pharmacy processes.
Group letter urging CMS to uphold the important protections under the 6PC policy as they implement the changes to the Part D program required under the IRA.
Group letter to CMS commenting on the Medicare Prescription Payment Plan (M3P) Draft 2 Guidance, recommending refinements to general outreach, education, and communication requirements for Part D sponsors, targeted outreach to patients likely to benefit, and election requirements.
Coalition letter to Ed & Workforce leadership commenting on the ERISA RFI, urging the committee to take action to reform step therapy and mark up the Safe Step Act (HR 2630)
Group letter urging the Biden administration not to draft a framework for the expanded use of March-In Rights, but instead the debate about product price as a triggering event for exercise of March-In Rights should occur in Congress.
Group letter urging the Administration to finalize the HHS rules no later than April 2024, to improve coverage and care for millions of patients and people with pre-existing conditions.
Group letter commenting on the 2018 AHP Rule, supporting the Department's proposal to rescind the 2018 AHP Rule and the proposed rule's explanation of DOL's pre-2018 approach to evaluating whether an association in bona fide under ERISA.
Group letter urging the Biden Administration to address drug shortages and underscore the urgency of strengthening pharmaceutical supply chain resilience in the upcoming State of the Union address.
Group letter supporting proposal to add clarification that all prescription drugs covered by ACA plans are subject to EHB protection, as well as urges survivorship habilitative and rehabilitative services to be included as EHBs. Additionally, supports the proposal to require all market place plans to meet minimum quantitative standards for network adequacy, increasing consumer protection and representation.
Coalition letter supporting the proposal to add clarification that all prescription drugs covered by ACA health plans, including large group and self-insured plans, are subject to EHB protections.